Advaxis Inc (ADXS) 2.65 $ADXS
Aratana Therapeutics Reports First Quarter 2014 Results
PR Newswire - Tue May 13, 3:01PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, today announced its first quarter 2014 financial results.
Advaxis Principal Investigator to Present ADXS-cHER2 Data in Canine Osteosarcoma at American College of Veterinary Internal Medicine Forum
GlobeNewswire - Tue May 13, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announced that principal investigator Nicola Mason, BVet.Med, PhD, DACVIM, of the University of Pennsylvania School of Veterinary Medicine, will present updated data from the ongoing ADXS-cHER2 study in canine osteosarcoma at the 2014 American College of Veterinary Internal Medicine (ACVIM) Forum on Thursday, June 5 at 4:25-5:15 p.m.in Nashville, TN. ADXS-cHER2 is an immunotherapy that targets the HER2 oncogene, which is overexpressed in certain solid-tumor cancers, including pediatric bone cancer and breast cancer. In her presentation, "Clinical Evaluation of a HER2/neu-Targeting Vaccine to Prevent Metastatic Osteosarcoma", Dr. Mason will provide updated data from the ongoing study in pet dogs with osteosarcoma.
Breast Cancer - Pipeline Review, H1 2014: 269 Companies Profiled
M2 - Thu May 08, 3:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5jqqdb/breast_cancer) has announced the addition of the "Breast Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Breast Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Breast Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Breast Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - 3-V Biosciences, Inc. - A&G Pharmaceutical, Inc. - A. Menarini Industrie Farmaceutiche Riunite Srl - AEterna Zentaris Inc. - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Advanced Cancer Therapeutics - Advaxis, Inc. - Advenchen Laboratories, LLC - Aegis Therapeutics, LLC - Affichem - Aileron Therapeutics, Inc. - Alchemia Limited - Alethia Biotherapeutics Inc. - Algeta ASA - Almac Discovery Ltd. - AlphaMab Co., Ltd - AlphaVax, Inc. - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Amplyx Pharmaceuticals, Inc. - Angion Biomedica Corp. - AntiCancer, Inc. - Antigen Express, Inc. - Antyra, Inc. - Aphios Corporation - Armour Therapeutics Inc. - Arno Therapeutics, Inc. - Arrien Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/5j...ast_cancer
Metastatic Breast Cancer - Pipeline Review, H1 2014: 83 Companies Profile
M2 - Thu May 08, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2bjnnz/metastatic_breast) has announced the addition of the "Metastatic Breast Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Breast Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Adherex Technologies Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - Agonox - AlphaMab Co., Ltd - Amarna Therapeutics B.V. - Amgen Inc. - Aphios Corporation - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca PLC - Bavarian Nordic A/S - BioMarin Pharmaceutical Inc. - BioNumerik Pharmaceuticals, Inc. - Biocon Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cell Therapeutics, Inc. - Celldex Therapeutics, Inc. - Celltrion, Inc. - Corcept Therapeutics Incorporated - Curadis GmbH - Curaxys, S.L. - Dainippon Sumitomo Pharma Co., Ltd. - Dompe Farmaceutici S.p.A. - EirGen Pharma Ltd. - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. and much more... For more information visit http://www.researchandmarkets.com/research/2b...tic_breast
Cervical Cancer - Pipeline Review, H1 2014: 48 Company and 82 Drugs Profiled
M2 - Wed May 07, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wpfpds/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved: - 3SBio Inc. - Advanced Cancer Therapeutics - Advaxis, Inc. - Amorfix Life Sciences Ltd. - Antigen Express, Inc. - ApoVax, Inc. - Arbor Vita Corporation - Azaya Therapeutics Incorporated - Bionor Pharma ASA - CEL-SCI Corporation - CZ BioMed Corp - Centre de Regulacio Genomica - Chong Kun Dang Pharmaceutical Corp. - Coridon Pty Ltd - Daiichi Sankyo Company, Limited - Dendreon Corporation - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Formune S.L. - Genetic Immunity, Inc - Genexine, Inc. - Genmab A/S - Genticel - Gilead Sciences, Inc. - GlaxoSmithKline plc - Helix BioPharma Corp. - ISA Pharmaceuticals B.V. - Indian Immunologicals Limited - LondonPharma Ltd - Med Discovery SA Drug Profiles: - hot water extract of mycobacterium tuberculosis - bevacizumab - (tegafur gimeracil oteracil potassium) - etirinotecan pegol - interferon alpha-2b - ADXS-HPV - ProCervix - hot water extract of mycobacterium tuberculosis - celecoxib - Triapine - exatecan mesylate - buparlisib hydrochloride - nimotuzumab - GSK-2141795 trametinib - TG-4001 - pazopanib hydrochloride - CIGB-228 Vaccine - CIGB-300 - nedaplatin [paclitaxel albumin-bound] - TA-HPV Vaccine - mapatumumab - artemether - HLA-A-0201 Restricted Specific Epitope Peptide Vaccine - ISA-101 - HuMax-TF ADC - PDS-0101 - docetaxel liposomal - Leukocyte Interleukin Injection - everolimus - GSK-2256098 For more information visit http://www.researchandmarkets.com/research/wp...cal_cancer
Advaxis, Inc. - "Pediatric Osteosarcoma: The First Indication in the ADXS-cHER2 Franchise"
ACCESSWIRE - Wed May 07, 8:56AM CDT
PRINCETON, NJ / ACCESSWIRE / May 7, 2014 / Advaxis, Inc. (NASDAQ: ADXS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Daniel J. O'Connor. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Advaxis to Initiate Clinical Development of ADXS-cHER2 Immunotherapy to Treat Pediatric Bone Cancer
GlobeNewswire - Mon May 05, 8:42AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announced it intends to initiate a clinical development program with its product candidate, ADXS-cHER2, for the treatment of pediatric osteosarcoma. ADXS-cHER2 is an immunotherapy that targets the HER2 oncogene, which is overexpressed in certain solid-tumor cancers, including pediatric bone cancer and breast cancer. In a veterinarian clinical study, pet dogs with naturally occurring osteosarcoma treated with ADXS-cHER2 after the standard of care showed a statistically significant prolonged overall survival benefit compared with dogs that received standard of care without ADXS-cHER2. Both veterinary and human osteosarcoma specialists consider canine osteosarcoma to be the best model for human osteosarcoma.
Advaxis, Inc. - "3 for 3 on Orphan Drug Requests"
ACCESSWIRE - Mon May 05, 6:51AM CDT
PRINCETON, N.J. / ACCESSWIRE / May 5, 2014 / Advaxis, Inc. (NASDAQ: ADXS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Daniel J. O'Connor. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Advaxis Receives Orphan Drug Designation for Treatment of Invasive Cervical Cancer
GlobeNewswire - Thu May 01, 6:30AM CDT
Advaxis, Inc., (Nasdaq:ADXS), a leader in developing cancer immunotherapies, announced today that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for ADXS-HPV, its lead immunotherapy drug candidate, for the treatment of Stage II-IV invasive cervical cancer.
Farrah Fawcett Foundation Announces $50,000 Grant To Brown University Oncology Research Group
PR Newswire - Wed Apr 30, 1:07PM CDT
The Farrah Fawcett Foundation (FFF) has presented a $50,000 grant to the Brown University Oncology Research Group (BrUOG) for "BrUOG 276: A Phase II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer," it was announced by Alana Stewart, President of The FFF. The grant will allow for the continued coordination and management of this novel clinical trial, representing an important step and sign of promise in anal cancer treatment.
Advaxis to Present at 2014 American Society of Clinical Oncology Annual Meeting
GlobeNewswire - Thu Apr 24, 7:45AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced that two abstracts related to ADXS-HPV (ADXS11-001), the Company's lead immunotherapy product candidate, have been selected for poster presentation at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 - June 3, 2014, at the McCormick Place in Chicago, IL.
Japan Patent Office Issues Advaxis a Notice of Allowance for Two Patent Applications Covering Its Cancer Immunotherapy Platform Technology
GlobeNewswire - Mon Apr 14, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that the Japan Patent Office issued to Advaxis two notices of allowance for two patent applications (P-72863-JP, P-7924) with claims for each patent application related to the Company's proprietary cancer immunotherapy platform technology. These patents will provide protection in Japan until 2030.
Pending Applications, Closed Public Offering, Joint Venture Formation, Executive Appointment, and Commercial Launch - Analyst Notes on Gilead, Enzymotec, Intrexon, Advaxis, and Repligen
PR Newswire - Tue Apr 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Enzymotec Ltd. (NASDAQ: ENZY), Intrexon Corporation (NYSE: XON), Advaxis, Inc. (NASDAQ: ADXS), and Repligen Corporation (NASDAQ: RGEN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Advaxis Receives Notice of Allowance From U.S. Patent and Trademark Office for Three Patent Applications With Multiple Claims Covering Its Cancer Immunotherapy Platform Technology
GlobeNewswire - Tue Apr 01, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for three U.S. patent applications (12/213,696, 13/254,607, and 11/415,271) with claims of each application related to the Company's proprietary cancer immunotherapy platform technology. The patent with the latest date of expiry is 2030, without taking into account patent term extension.
Advaxis Announces Closing of Public Offering of Common Stock
GlobeNewswire - Mon Mar 31, 3:37PM CDT
Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company"
, today announced the closing of a previously announced underwritten public offering of 4,692,000 shares of its common stock, including the fully exercised over-allotment option by the underwriters covering 612,000 shares, offered at a price to the public of $3.00 per share. The gross proceeds to the Company were $14,076,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.
Moskowitz: Advaxis Balance Sheet Shored Up
ACCESSWIRE - Mon Mar 31, 8:40AM CDT
Read the Advaxis Report Update: http://equitiesiq.com/reports/advaxis-update/
Advaxis Announces Full Exercise of Underwriters' Over-Allotment Option
GlobeNewswire - Fri Mar 28, 2:00PM CDT
Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company" , today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 612,000 shares of its common stock at a public offering price of $3.00 per share in connection with its previously announced underwritten public offering of 4,080,000 shares of common stock, bring the total gross proceeds from the offering to approximately $14,076,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.
Team Nation Holdings Corp Officially Changes its Name; Petr Shares Rise on Brazil Outlook Upgrade
ACCESSWIRE - Thu Mar 27, 11:37PM CDT
Petr (NYSE: PBR) - For an in-depth report on Petr follow: www.BullTrends.com/stockquote/PBR
Nasdaq stocks posting largest volume increases
AP - Thu Mar 27, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Advaxis Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Mar 26, 7:40PM CDT
Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company" , today announced the pricing of an underwritten public offering of 4,080,000 shares of common stock at a public offering price of $3.00 per share. The Company expects to receive $12,240,000 in gross proceeds, before deducting underwriting discounts and commissions and offering expenses payable by the Company. The Company has granted the underwriters a 45-day option to purchase up to 612,000 additional shares of common stock. The Company intends to use the net proceeds from this offering to fund the Company's continued research and development initiatives in connection with expanding its product line and for other general corporate purposes.
Aratana Therapeutics Reports First Quarter 2014 Results
PR Newswire - Tue May 13, 3:01PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, today announced its first quarter 2014 financial results.
Advaxis Principal Investigator to Present ADXS-cHER2 Data in Canine Osteosarcoma at American College of Veterinary Internal Medicine Forum
GlobeNewswire - Tue May 13, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announced that principal investigator Nicola Mason, BVet.Med, PhD, DACVIM, of the University of Pennsylvania School of Veterinary Medicine, will present updated data from the ongoing ADXS-cHER2 study in canine osteosarcoma at the 2014 American College of Veterinary Internal Medicine (ACVIM) Forum on Thursday, June 5 at 4:25-5:15 p.m.in Nashville, TN. ADXS-cHER2 is an immunotherapy that targets the HER2 oncogene, which is overexpressed in certain solid-tumor cancers, including pediatric bone cancer and breast cancer. In her presentation, "Clinical Evaluation of a HER2/neu-Targeting Vaccine to Prevent Metastatic Osteosarcoma", Dr. Mason will provide updated data from the ongoing study in pet dogs with osteosarcoma.
Breast Cancer - Pipeline Review, H1 2014: 269 Companies Profiled
M2 - Thu May 08, 3:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5jqqdb/breast_cancer) has announced the addition of the "Breast Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Breast Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Breast Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Breast Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - 3-V Biosciences, Inc. - A&G Pharmaceutical, Inc. - A. Menarini Industrie Farmaceutiche Riunite Srl - AEterna Zentaris Inc. - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Advanced Cancer Therapeutics - Advaxis, Inc. - Advenchen Laboratories, LLC - Aegis Therapeutics, LLC - Affichem - Aileron Therapeutics, Inc. - Alchemia Limited - Alethia Biotherapeutics Inc. - Algeta ASA - Almac Discovery Ltd. - AlphaMab Co., Ltd - AlphaVax, Inc. - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Amplyx Pharmaceuticals, Inc. - Angion Biomedica Corp. - AntiCancer, Inc. - Antigen Express, Inc. - Antyra, Inc. - Aphios Corporation - Armour Therapeutics Inc. - Arno Therapeutics, Inc. - Arrien Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/5j...ast_cancer
Metastatic Breast Cancer - Pipeline Review, H1 2014: 83 Companies Profile
M2 - Thu May 08, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2bjnnz/metastatic_breast) has announced the addition of the "Metastatic Breast Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Breast Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Adherex Technologies Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - Agonox - AlphaMab Co., Ltd - Amarna Therapeutics B.V. - Amgen Inc. - Aphios Corporation - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca PLC - Bavarian Nordic A/S - BioMarin Pharmaceutical Inc. - BioNumerik Pharmaceuticals, Inc. - Biocon Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cell Therapeutics, Inc. - Celldex Therapeutics, Inc. - Celltrion, Inc. - Corcept Therapeutics Incorporated - Curadis GmbH - Curaxys, S.L. - Dainippon Sumitomo Pharma Co., Ltd. - Dompe Farmaceutici S.p.A. - EirGen Pharma Ltd. - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. and much more... For more information visit http://www.researchandmarkets.com/research/2b...tic_breast
Cervical Cancer - Pipeline Review, H1 2014: 48 Company and 82 Drugs Profiled
M2 - Wed May 07, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wpfpds/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved: - 3SBio Inc. - Advanced Cancer Therapeutics - Advaxis, Inc. - Amorfix Life Sciences Ltd. - Antigen Express, Inc. - ApoVax, Inc. - Arbor Vita Corporation - Azaya Therapeutics Incorporated - Bionor Pharma ASA - CEL-SCI Corporation - CZ BioMed Corp - Centre de Regulacio Genomica - Chong Kun Dang Pharmaceutical Corp. - Coridon Pty Ltd - Daiichi Sankyo Company, Limited - Dendreon Corporation - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Formune S.L. - Genetic Immunity, Inc - Genexine, Inc. - Genmab A/S - Genticel - Gilead Sciences, Inc. - GlaxoSmithKline plc - Helix BioPharma Corp. - ISA Pharmaceuticals B.V. - Indian Immunologicals Limited - LondonPharma Ltd - Med Discovery SA Drug Profiles: - hot water extract of mycobacterium tuberculosis - bevacizumab - (tegafur gimeracil oteracil potassium) - etirinotecan pegol - interferon alpha-2b - ADXS-HPV - ProCervix - hot water extract of mycobacterium tuberculosis - celecoxib - Triapine - exatecan mesylate - buparlisib hydrochloride - nimotuzumab - GSK-2141795 trametinib - TG-4001 - pazopanib hydrochloride - CIGB-228 Vaccine - CIGB-300 - nedaplatin [paclitaxel albumin-bound] - TA-HPV Vaccine - mapatumumab - artemether - HLA-A-0201 Restricted Specific Epitope Peptide Vaccine - ISA-101 - HuMax-TF ADC - PDS-0101 - docetaxel liposomal - Leukocyte Interleukin Injection - everolimus - GSK-2256098 For more information visit http://www.researchandmarkets.com/research/wp...cal_cancer
Advaxis, Inc. - "Pediatric Osteosarcoma: The First Indication in the ADXS-cHER2 Franchise"
ACCESSWIRE - Wed May 07, 8:56AM CDT
PRINCETON, NJ / ACCESSWIRE / May 7, 2014 / Advaxis, Inc. (NASDAQ: ADXS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Daniel J. O'Connor. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Advaxis to Initiate Clinical Development of ADXS-cHER2 Immunotherapy to Treat Pediatric Bone Cancer
GlobeNewswire - Mon May 05, 8:42AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announced it intends to initiate a clinical development program with its product candidate, ADXS-cHER2, for the treatment of pediatric osteosarcoma. ADXS-cHER2 is an immunotherapy that targets the HER2 oncogene, which is overexpressed in certain solid-tumor cancers, including pediatric bone cancer and breast cancer. In a veterinarian clinical study, pet dogs with naturally occurring osteosarcoma treated with ADXS-cHER2 after the standard of care showed a statistically significant prolonged overall survival benefit compared with dogs that received standard of care without ADXS-cHER2. Both veterinary and human osteosarcoma specialists consider canine osteosarcoma to be the best model for human osteosarcoma.
Advaxis, Inc. - "3 for 3 on Orphan Drug Requests"
ACCESSWIRE - Mon May 05, 6:51AM CDT
PRINCETON, N.J. / ACCESSWIRE / May 5, 2014 / Advaxis, Inc. (NASDAQ: ADXS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Daniel J. O'Connor. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Advaxis Receives Orphan Drug Designation for Treatment of Invasive Cervical Cancer
GlobeNewswire - Thu May 01, 6:30AM CDT
Advaxis, Inc., (Nasdaq:ADXS), a leader in developing cancer immunotherapies, announced today that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for ADXS-HPV, its lead immunotherapy drug candidate, for the treatment of Stage II-IV invasive cervical cancer.
Farrah Fawcett Foundation Announces $50,000 Grant To Brown University Oncology Research Group
PR Newswire - Wed Apr 30, 1:07PM CDT
The Farrah Fawcett Foundation (FFF) has presented a $50,000 grant to the Brown University Oncology Research Group (BrUOG) for "BrUOG 276: A Phase II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer," it was announced by Alana Stewart, President of The FFF. The grant will allow for the continued coordination and management of this novel clinical trial, representing an important step and sign of promise in anal cancer treatment.
Advaxis to Present at 2014 American Society of Clinical Oncology Annual Meeting
GlobeNewswire - Thu Apr 24, 7:45AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced that two abstracts related to ADXS-HPV (ADXS11-001), the Company's lead immunotherapy product candidate, have been selected for poster presentation at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 - June 3, 2014, at the McCormick Place in Chicago, IL.
Japan Patent Office Issues Advaxis a Notice of Allowance for Two Patent Applications Covering Its Cancer Immunotherapy Platform Technology
GlobeNewswire - Mon Apr 14, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that the Japan Patent Office issued to Advaxis two notices of allowance for two patent applications (P-72863-JP, P-7924) with claims for each patent application related to the Company's proprietary cancer immunotherapy platform technology. These patents will provide protection in Japan until 2030.
Pending Applications, Closed Public Offering, Joint Venture Formation, Executive Appointment, and Commercial Launch - Analyst Notes on Gilead, Enzymotec, Intrexon, Advaxis, and Repligen
PR Newswire - Tue Apr 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Enzymotec Ltd. (NASDAQ: ENZY), Intrexon Corporation (NYSE: XON), Advaxis, Inc. (NASDAQ: ADXS), and Repligen Corporation (NASDAQ: RGEN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Advaxis Receives Notice of Allowance From U.S. Patent and Trademark Office for Three Patent Applications With Multiple Claims Covering Its Cancer Immunotherapy Platform Technology
GlobeNewswire - Tue Apr 01, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for three U.S. patent applications (12/213,696, 13/254,607, and 11/415,271) with claims of each application related to the Company's proprietary cancer immunotherapy platform technology. The patent with the latest date of expiry is 2030, without taking into account patent term extension.
Advaxis Announces Closing of Public Offering of Common Stock
GlobeNewswire - Mon Mar 31, 3:37PM CDT
Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company"
, today announced the closing of a previously announced underwritten public offering of 4,692,000 shares of its common stock, including the fully exercised over-allotment option by the underwriters covering 612,000 shares, offered at a price to the public of $3.00 per share. The gross proceeds to the Company were $14,076,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. Moskowitz: Advaxis Balance Sheet Shored Up
ACCESSWIRE - Mon Mar 31, 8:40AM CDT
Read the Advaxis Report Update: http://equitiesiq.com/reports/advaxis-update/
Advaxis Announces Full Exercise of Underwriters' Over-Allotment Option
GlobeNewswire - Fri Mar 28, 2:00PM CDT
Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company"
, today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 612,000 shares of its common stock at a public offering price of $3.00 per share in connection with its previously announced underwritten public offering of 4,080,000 shares of common stock, bring the total gross proceeds from the offering to approximately $14,076,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. Team Nation Holdings Corp Officially Changes its Name; Petr Shares Rise on Brazil Outlook Upgrade
ACCESSWIRE - Thu Mar 27, 11:37PM CDT
Petr (NYSE: PBR) - For an in-depth report on Petr follow: www.BullTrends.com/stockquote/PBR
Nasdaq stocks posting largest volume increases
AP - Thu Mar 27, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Advaxis Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Mar 26, 7:40PM CDT
Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company"
, today announced the pricing of an underwritten public offering of 4,080,000 shares of common stock at a public offering price of $3.00 per share. The Company expects to receive $12,240,000 in gross proceeds, before deducting underwriting discounts and commissions and offering expenses payable by the Company. The Company has granted the underwriters a 45-day option to purchase up to 612,000 additional shares of common stock. The Company intends to use the net proceeds from this offering to fund the Company's continued research and development initiatives in connection with expanding its product line and for other general corporate purposes. 
